James A. Knost

2.3k citations

45 papers · 1.7k indexed · h-index 21

Impact in

Oncology top 5%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
Pathology and Forensic Medicine top 5%
- Phytoestrogen effects and research

Papers in

Oncology 28
- Colorectal Cancer Treatments and Studies 16
- Cancer Treatment and Pharmacology 7
- Cancer Immunotherapy and Biomarkers 4
Cancer Research 8
- Cancer Genomics and Diagnostics 6

Co-authors: Charles L. Loprinzi Jeff A. Sloan Paul J. Novotny Kathy D. Miller Beth LaVasseur Debra L. Barton Paul G. Abrams Susan K. Quella
Journals: Journal of Clinical Oncology (15 papers)Investigational New Drugs (3 papers)Cancer (2 papers)Gynecologic Oncology (2 papers)Annals of Oncology (2 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

James A. Knost

45 papers receiving 1.6k citations

Peers

Countries citing papers authored by James A. Knost

Since Specialization

Citations

This map shows the geographic impact of James A. Knost's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James A. Knost with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James A. Knost more than expected).

Fields of papers citing papers by James A. Knost

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James A. Knost. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James A. Knost. The network helps show where James A. Knost may publish in the future.

Co-authors

The 25 scholars most cited alongside James A. Knost, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with James A. Knost Line = papers co-authored together James A. Knost links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Clinical Cancer Research ·Aparna R. Parikh, Fa-Chyi Lee, Linda Yau, Han Koh, James A. Knost, Edith P. Mitchell, ARIF ALI, Nicholas W. Choong, Frank A. Scappaticci, Christoph Mancao, Heinz‐Josef Lenz	2018	39
2	Clinical germline diagnostic exome sequencing for hereditary cancer: Findings within novel candidate genes are prevalent Cancer Genetics ·Zöe Powis, Carin R. Espenschied, Holly LaDuca, Kelly D. Farwell Hagman, Eglantina Zyko, Shuwei Li, Hiroto Inaba, Ann M. Mauer, Katherine L. Nathanson, James A. Knost, Elizabeth Chao, Sha Tang	2018	3
3	Significant and durable clinical benefit from trastuzumab in 2 patients with HER2‐amplified salivary gland cancer and a review of the literature Head & Neck ·Lauren M. Thorpe, Alexa B. Schrock, Rachel Erlich, Vincent A. Miller, James A. Knost, Nguyet Le‐Lindqwister, A. Perez-Soba, Siraj M. Ali, Jane J. Liu	2016	33
4	The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases Familial Cancer ·Leora Witkowski, S. Y. Ding, Lingui Xu, James A. Knost, Steffen Albrecht, Andrew Berchuck, W. Glenn McCluggage, Martin Hasselblatt, William D. Foulkes	2016	24
5	The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type Gynecologic Oncology ·Leora Witkowski, Catherine Goudie, Pilar Ramos, Talia Boshari, Jean‐Sébastien Brunet, Anthony N. Karnezis, Michel Longy, James A. Knost, Emmanouil Saloustros, W. Glenn McCluggage, Colin J.R. Stewart, William P.D. Hendricks, Heather E. Cunliffe, David G. Huntsman, Patricia Pautier, Douglas A. Levine, Jeffrey M. Trent, Andrew Berchuck, Martin Hasselblatt, William D. Foulkes	2016	86
6	Lung sarcomatoid carcinoma (LSC) harbors targetable genomic alterations and high mutational burden as observed by comprehensive genomic profiling (CGP) Annals of Oncology ·Balázs Halmos, Garrett M. Frampton, James Suh, Jonathan Alexander Lema Vargas, Ranee Mehra, Stephen H. Buck, José A. Bufill, Nir Peled, Nagla Abdel Karim, Paul A. S. Fishkin, James A. Knost, S.-H.I. Ou, Tran Ha Phuong, Ferran Gonzàlez, V. A. Miller, Siraj M. Ali, Proner	2016	2
7	Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer Cancer Chemotherapy and Pharmacology ·Muhammad Wasif Saif, James A. Knost, E. Gabriela Chiorean, H L Brantley, Danni Yu, Bronislaw Pytowski, Amy Qin, John Kauh, Bert H. O’Neil	2016	56
8	Colorectal cancer (CRC) cohort analysis of patients treated with buparlisib in a distinctive tissue-agnostic trial model for molecularly preselected tumors. Journal of Clinical Oncology ·Sarina A. Piha‐Paul, James A. Knost, Petros Nikolinakos, Lee S. Schwartzberg, Denise A. Yardley, Eric D. Slosberg, Barinder Kang, James E. Vinton, Claudia Lebedinsky	2015	1
9	Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium Investigational New Drugs ·Manish Sharma, Kristen Wroblewski, Blasé N. Polite, James A. Knost, James A. Wallace, Sanjiv Modi, Bethany Sleckman, David Taber, Everett E. Vokes, Walter M. Stadler, Hedy L. Kindler	2011	43
10	A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia Gynecologic Oncology ·Halla Nimeiri, Amit M. Oza, Robert J. Morgan, Dezheng Huo, Laurie Elit, James A. Knost, James L. Wade, Edem Agamah, Everett E. Vokes, Gini F. Fleming	2010	71
11	Phase II Study of Preoperative Pemetrexed, Carboplatin, and Radiation Followed by Surgery for Locally Advanced Esophageal Cancer and Gastroesophageal Junction Tumors Journal of Thoracic Oncology ·Aminah Jatoi, Gamini S. Soori, Nathan R. Foster, Stéphane Chemouny, James A. Knost, Tom R. Fitch, Matthew D. Callister, Francis C. Nichols, Elshan Ghojehbiglou, Steven R. Alberts	2010	18
12	Small Interfering RNA–Directed Knockdown of Uracil DNA Glycosylase Induces Apoptosis and Sensitizes Human Prostate Cancer Cells to Genotoxic Stress Molecular Cancer Research ·Sai Murali Krishna Pulukuri, James A. Knost, Norman Estes, Jasti S. Rao	2009	35
13	A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma Investigational New Drugs ·Amy Peterson, Helena Harlin, Theodore Karrison, Nicholas J. Vogelzang, James A. Knost, John W. Kugler, Eric P. Lester, Everett E. Vokes, Thomas F. Gajewski, Walter M. Stadler	2006	17
14	Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group Annals of Oncology ·Poramin Sananunsakul, Brian R. Murphy, Nathan R. Foster, Daniel A. Nikcevich, Steven R. Alberts, James A. Knost, Tom R. Fitch, Kendrith M. Rowland	2005	52
15	Long-Term Survival of Patients With Advanced/Recurrent Carcinoma of Cervix and Vagina After Neoadjuvant Treatment With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without the Addition of Molgramostim, and Review of the Literature American Journal of Clinical Oncology ·Harry J. Long, Noé Contreras-Gonz alez, Karl C. Podratz, S N Nakhwa, Vera J. Suman, Lynn C. Hartmann, Ralph Levitt, Suresh Nair, Alan K. Hatfield, James A. Knost	2002	12
16	Comparison of Lymphoid Neoplasm Classification American Journal of Clinical Pathology ·С О Носов, D. M. Urazkulova, Paul A. S. Fishkin, James A. Knost, CH Patil, Bassam N. Smir, Fiona E. Craig	2001	9
17	Utility of flow cytometry in subtyping composite and sequential lymphoma Journal of Clinical Laboratory Analysis ·С О Носов, Hanna Syahrina Arumndalu, Allen M. Vukov, James A. Knost, RattanS Rashpa, Fiona E. Craig	1999	11
18	Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer Investigational New Drugs ·Sridhar Mani, John W. Kugler, James A. Knost, Monique E. DePaepe, Joseph Gibbons, Juan Carlos García‐Ruiz, Rafat Ansari, Richard L. Schilsky, Everett E. Vokes	1998	27
19	Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. Journal of Clinical Oncology ·Henry C. Pitot, Donald B. Wender, Matthew J. O’Connell, Georgene Schroeder, Richard M. Goldberg, Joseph Rubin, J A Mailliard, James A. Knost, C Ghosh, Anna Torres Lacomba, Ralph Levitt, Harold E. Windschitl	1997	220
20	Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. Journal of Clinical Oncology ·Robert M. Goldberg, Alan K. Hatfield, Michael Kahn, Daniel J. Sargent, James A. Knost, M J O'Connell, James E. Krook, Sylwester Kot, Martin Wiesenfeld, E. Moroni, Maria Tria Tirona, C G Moertel	1997	35

About James A. Knost

James A. Knost is a scholar working on Oncology, Cancer Research, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Obstetrics and Gynecology, having authored 45 papers that have together received 1.7k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (16 papers), Lung Cancer Treatments and Mutations (7 papers), Cancer Treatment and Pharmacology (7 papers), Cancer Genomics and Diagnostics (6 papers), Cancer Immunotherapy and Biomarkers (4 papers), Lymphoma Diagnosis and Treatment (4 papers), Chromatin Remodeling and Cancer (3 papers) and Immunotherapy and Immune Responses (3 papers). The work is most often cited by research in Oncology (764 citations), Pathology and Forensic Medicine (429 citations), Hepatology (112 citations), Endocrinology, Diabetes and Metabolism (174 citations) and Obstetrics and Gynecology (79 citations). James A. Knost has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Charles L. Loprinzi, Jeff A. Sloan, Paul J. Novotny, Kathy D. Miller, Beth LaVasseur, Debra L. Barton, Paul G. Abrams, Susan K. Quella, Ralph Levitt and Harold E. Windschitl. Their work appears in journals such as Journal of Clinical Oncology, Investigational New Drugs, Cancer, Gynecologic Oncology and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact